CSPC Pharmaceutical Group Ltd. has announced that its Meloxicam Injection $(III.UK)$ has received drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is indicated for the treatment of moderate to severe pain in adults and is the first intravenously administered nanocrystal product approved in China. Utilizing novel nanotechnology, this formulation allows for high-dose, rapid intravenous administration, offering a rapid onset and long-lasting analgesic effects for acute postoperative pain. This approval marks a significant advancement for CSPC in the field of nanomedicine research and development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.